The HER2 (c-erbB-2) oncogene is frequently amplified in in situ carcinomas of the breast.
The HER2 (c-erbB-2) oncogene is frequently amplified in in situ carcinomas of the breast.
复制标题
DOI：
--
复制
发表时间：
1992-05
期刊：
影响因子：
8
通讯作者：
E. T. Liu;A. Thor;M. He;M. Barcos;B. Ljung;C. Benz
中科院分区：
文献类型：
--
作者：
E. T. Liu;A. Thor;M. He;M. Barcos;B. Ljung;C. Benz
在来自 27 个乳腺癌原位癌和 122 个 II 期乳腺癌的石蜡包埋标本中评估了 HER2 (c-erbB-2) 癌基因的扩增和过度表达。通过差异聚合酶链式反应 (PCR) 在这些档案组织中检测到基因扩增，发现在 48% 的原位癌和 21% 的 II 期病变中（chi 2 = 7.62，p 小于或等于 0.01）。此外，对于原位癌症（p小于或等于0.025）和II期癌症（p小于或等于0.0005），基因扩增水平与通过免疫组织化学测量的HER2癌蛋白表达水平相关。在非侵袭性乳腺肿瘤中，HER2 基因扩增的高发生率以及伴随的过度表达表明 HER2 癌基因的扰动是人类乳腺癌中最早和最常见的遗传病变之一。
Amplification and overexpression of the HER2 (c-erbB-2) oncogene was assessed in paraffin-embedded specimens from 27 in situ carcinomas of the breast and from 122 stage II breast cancers. Gene amplification detected in these archival tissues by differential polymerase chain reaction (PCR) was found in 48% of in situ carcinomas and in 21% of stage II lesions (chi 2 = 7.62, p less than or equal to 0.01). In addition, the level of gene amplification correlated with the level of HER2 oncoprotein expression as measured by immunohistochemistry for both in situ cancers (p less than or equal to 0.025) and stage II cancers (p less than or equal to 0.0005). This high incidence of HER2 gene amplification with accompanying overexpression in non-invasive breast tumors suggests that perturbations of the HER2 oncogene are among the earliest and most common genetic lesions in human breast cancer.